Nicole Beaulieu Perez, PhD, RN, PMHNP-BC, an assistant nursing professor at NYU Rory Meyers College of Nursing

Monocyte Aging Links to Non-Somatic Depression Symptoms, With Nicole Perez, PhD

Depression heterogeneity may obscure biologically meaningful signals, but new data suggest monocyte-specific epigenetic aging could help differentiate symptom domains. In an interview with 

, Nicole Beaulieu Perez, PhD, RN, PMHNP-BC, an assistant nursing professor at NYU Rory Meyers College of Nursing, said the findings reinforce a central clinical reality: "Depression is not a monolith,” with distinct symptom profiles potentially reflecting different underlying mechanisms.

“We see all the time in practice how patients present with a variety of presentations,” Perez said. “We know there's over 200 possible combinations of symptoms that get us that disorder of depression. What's been less clear is how those presentations have been linked differentially to underlying biology. What goes with that is that we see all the time that patients respond differently to medications that target different mechanisms, even though they have the same diagnosis. This study…is consistent with what we're seeing in that we found that the epigenetic aging and monocytes using this new clock monocyte age acceleration showed differential associations when we looked at symptoms of depression that were considered non-somatic.”

Non-somatic symptoms include profound hopelessness and anhedonia. Meanwhile, the study did not show a link between monocyte age acceleration and somatic symptoms, including fatigue and the inability to fall asleep.

“When we actually drill down and look at a symptom resolution lens of what symptoms people are experiencing, we see biological differences, and specifically in this study, having to do with the accelerated aging of monocytes,” she added.

The study analyzed 440 participants from the Women’s Interagency HIV Study, including 261 women with HIV (mean age, 43.7 years), evaluating associations between epigenetic age acceleration (EAA) and depressive symptoms measured by the Center for Epidemiologic Studies Depression Scale (CES-D). Investigators compared a monocyte-derived clock (MonoDNAmAge) with a multi-tissue clock (HorvathDNAmAge), focusing on symptom domains rather than total scores.

In adjusted models, monocyte EAA was associated with non-somatic depressive symptoms (

=.018), with particularly strong associations for anhedonia (

=.007). No associations were observed for somatic symptoms such as fatigue or sleep disturbance at the domain level. Horvath-based EAA was not associated with total or domain-specific depressive symptoms.

Although the findings do not alter current diagnostic criteria for major depressive disorder (MDD), they support a more granular approach to symptom assessment. Perez noted that clinicians already differentiate symptom patterns in practice, but existing frameworks and tools may not adequately capture this heterogeneity.

She pointed to limitations of total scores from commonly used scales such as the CES-D. These instruments aggregate symptoms across multiple domains, despite depression being a multidimensional construct encompassing affective, cognitive, and somatic features.

“Someone could have the same score at 2 different time points but totally different symptoms,” Perez said. “It’s misleading to think that necessarily their symptoms are the same over time.”

Biomarker Potential and Biological Context

The study also advances interest in monocyte epigenetic aging as a potential biomarker for depression. However, its clinical role remains uncertain. Because the analysis was cross-sectional, it cannot determine whether monocyte EAA reflects a state marker of current symptom burden or a trait marker of vulnerability.

The findings may be particularly relevant for populations with elevated inflammatory burden. Women living with HIV experience greater rates of depression and chronic comorbidities, alongside social and structural stressors that may contribute to “biological weathering,” a process linking environmental adversity to accelerated aging.

The selective association between monocyte aging and non-somatic symptoms supports emerging models of depression subtypes, including inflammation-related phenotypes characterized by anhedonia and affective disturbance. By contrast, the absence of associations with somatic symptoms highlights the importance of domain-specific analyses. Overall, the study suggests that aligning biological measures with specific symptom dimensions may improve signal detection and advance precision psychiatry.

“I don't think it's ready for prime time yet,” Perez said. “What we're seeing here is that folks [who] have distinct presentations are going to have different biological mechanisms at play.”

Perez NB, Xu K, Xu Y, et al. Monocyte Epigenetic Age Acceleration is Linked to Non-Somatic Depressive Symptoms in Women with and Without HIV. 

Videos

In this interview, Perez discusses data linking monocyte epigenetic age acceleration to non-somatic depressive symptoms.


News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

The international Tokyo Guidelines 2018 recommend 4 to 7 days of antibiotic treatment after adequate biliary drainage, with observational data prompting investigators to conduct the non-inferiority COBRA trial to assess whether shorter treatment may be sufficient for adults with acute 

2026 show that 1 day of antibiotic therapy after adequate endoscopic biliary drainage was noninferior compared to 4 to 7 days in adults with acute cholangitis, with investigators suggesting 1 day should be the preferred duration of antibiotic treatment.

Background on Acute Cholangitis and Post- Adequate Biliary Drainage Duration of Antibiotic Treatment

If not treated promptly, acute cholangitis can lead to sepsis, with general hospital mortality for biliary sepsis around 21%, and even up to 40% in severe septic shock cases.

Study investigators describe the achievement of adequate biliary drainage by endoscopic retrograde cholangiopancreatography (ERCP) as the cornerstone of therapeutic management for acute cholangitis.

While the Tokyo Guidelines 2018 recommend an antibiotic duration of 4 to 7 days, contradicting guidelines have led to varying clinical practice decisions. For example, the Dutch national sepsis treatment guidelines state that an antibiotic treatment of 1 to 3 days is adequate after source control.

The variation across guidelines can lead to inconsistencies in clinical practice regarding the duration of antibiotic treatment, with time ranging from 1 to 13 days after ERCP.

To examine the range in antibiotic treatment duration, study investigators conducted a multicenter, open-label, parallel group randomized controlled non-inferiority trial in 31 hospitals in the Netherlands. The primary objective was to assess whether a short-course of antibiotic treatment, defined as 1 day, following adequate biliary drainage, is non-inferior to a longer course of antibiotic treatment, defined as 4 to 7 days, in achieving clinical cure.

Investigators defined the primary outcome as clinical cure, with a patient being free of symptoms by day 14 after ERCP, with no relapse or death occurring by day 30. The primary endpoint was adjudicated by an independent blinded committee. The intention-to-treat and per-protocol populations were analyzed, and the absolute risk difference for clinical cure was calculated. Investigators deemed that non-inferiority was demonstrated if the one-sided 95% confidence limit for the absolute risk difference was > -7.5%.

They randomly assigned 413 patients with acute cholangitis due to distal biliary obstruction who achieved adequate endoscopic biliary drainage and fever resolution within 24 hours after ERCP, in a 1:1 ratio, to receive antibiotics for 1 day (n = 205) or 4 to 7 days (n = 208) after ERCP.

The average age of COBRA’s patient population was 74 years, 43.4% were women, 10.0% had malignant obstruction, 57.6% had moderate/severe cholangitis, and 35.6% had gram-negative bacteraemia at the time of randomization. 3 patients in the 4 to 7 day group were lost to follow-up before the primary outcome could be assessed, excluding them from all analyses, and marking a 93.0% adherence to the allocated antibiotic treatment duration.

In the intention-to-treat analysis, investigators observed that the primary outcome occurred in 95.1% of patients (195/205) in the 1-day group compared to 93.7% in the 4 to 7 day group (192/205), with an absolute risk difference of 1.5% (one-sided 95% confidence limit: -2.4%), demonstrating non-inferiority.

A per-protocol analysis (n = 384) showed non-inferiority (absolute risk difference 0.6%, with one-sided 95% confidence limit: -3.2%). In a worst-case sensitivity analysis (with lost to follow-up counting as failures), non-inferiority was maintained. All-cause 30-day mortality was 2/205 in the 1-day group compared to 1/205 in the 4 to 7-day group.

Based on these results, investigators concluded that 1 day of antibiotic treatment after adequate endoscopic biliary drainage is non-inferior to 4 to 7 days in adults with acute cholangitis. Therefore, they suggest that 1 day should be the preferred duration of antibiotic treatment after adequate biliary drainage.

Overdevest AG, Sieswerda E, Haal S, et al. Antibiotic treatment for 1 day versus 4–7 days in patients with acute cholangitis after adequate endoscopic biliary drainage (COBRA): study protocol for a randomized controlled trial. 

https://doi.org/10.1186/s13063-026-09524-7

Anouk Overdevest. ONE DAY OF ANTIBIOTIC TREATMENT IS NON-INFERIOR TO 4 - 7 DAYS IN PATIENTS WITH ACUTE CHOLANGITIS AFTER ADEQUATE BILIARY DRAINAGE (COBRA): A MULTI-CENTER RANDOMIZED CONTROLLED TRIAL. Poster presented at: Digestive Disease Week; May 2-5, 2026; Chicago, IL.

Beliaev AM, Sof'ya Zyul'korneeva, Rowbotham D, Bergin CJ. Screening acute cholangitis patients for sepsis. 

Articles

Adequate source control via ERCP is central to acute cholangitis management, yet post-drainage antibiotic duration remains heterogeneous across guidelines and practice. In the multicenter, open-label COBRA non-inferiority RCT across 31 Dutch hospitals, 413 adults with distal biliary obstruction, successful endoscopic drainage, and fever resolution within 24 hours were randomized to 1 day versus 4–7 days of antibiotics. Clinical cure at day 14 without relapse/death by day 30 was comparable, meeting non-inferiority in intention-to-treat and per-protocol analyses.

COBRA findings suggest 1 day of antibiotic treatment is preferred in acute cholangitis after adequate biliary drainage compared to longer guidelines.


Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Hepatology

Shorter Antibiotic Treatment After Adequate Biliary Drainage Non-Inferior in Acute Cholangitis

Edward Barnes, MD, MPH, is an associate professor of medicine in the division of gastroenterology and hepatology and co-director of the Multidisciplinary Inflammatory Bowel Diseases Center at the University of North Carolina at Chapel Hill.

Mirikizumab After Anti-TNF Failure: New Crohn’s Disease Data Explained

 who have already cycled through first-line biologic therapy, treatment decisions become increasingly complex while the likelihood of achieving meaningful, durable remission often declines. As more advanced therapies enter the market, clinicians are left navigating which agents can still deliver strong outcomes after anti-TNF failure.

New data presented at Digestive Disease Week (DDW) 2026 in Chicago, IL, begin to address that question, offering insight into the performance of mirikizumab in a second-line setting. In an interview with HCPLive, Edward Barnes, MD, MPH, discussed findings from a post hoc analysis of the VIVID clinical trial program, focusing specifically on patients who had experienced failure of a single anti-TNF agent.

Mirikizumab Maintains Disease Clearance in UC Through 4 Years in LUCENT-3 Extension

As Barnes emphasized, this population closely reflects the patients seen in routine clinical practice: those with moderate to severe disease who often have fewer effective options remaining. Historically, treatment response tends to diminish with each subsequent line of therapy, underscoring the importance of identifying therapies that maintain efficacy beyond first-line use.

VIVID Trial Data Highlight Clinical and Endoscopic Efficacy

The present analysis drew from patients enrolled in VIVID-1 and its open-label extension, VIVID-2, who had failed 1 prior anti-TNF therapy and had not been exposed to other advanced treatments. Outcomes assessed included clinical remission based on the Crohn’s Disease Activity Index (CDAI) and endoscopic response over time.

Results demonstrated clear separation between mirikizumab and placebo. By week 12, patients receiving mirikizumab had already shown improvements in clinical response and patient-reported outcomes.

Of note, these gains deepened over time, with statistically significant differences observed at week 52. At that point, 44.0% of patients treated with mirikizumab achieved CDAI remission compared with 15.5% in the placebo group (

<.001). Endoscopic response rates followed a similar pattern, with 37.1% of mirikizumab-treated patients achieving response versus 6.9% of those receiving placebo (

Treat-to-Target Approach Reflected in “Treat-Through” Study Design

A key strength of the VIVID program, according to Barnes, is its “treat-through” design, which avoids treatment interruption and more closely mirrors real-world practice. This framework aligns with treat-to-target strategies in inflammatory bowel disease, where initial symptomatic improvement is followed by objective measures such as biomarker normalization and endoscopic healing.

“You see patients feel well first, and then over time, they achieve those deeper endpoints,” Barnes explained, noting that while some patients achieved early endoscopic response, the most robust outcomes emerged with continued therapy through one year.

“We saw patients feel well first, and then the longer we followed them on the therapy, they then met the other endpoints that we would expect,” Barnes said. “It's not to say that, you know, a quarter of patients weren't already hitting endoscopic response by that 12 week period, but the longer the patients were on therapy, they continued to feel well.”

Durable Remission Supports Long-Term Use of IL-23 Inhibition

Long-term data from VIVID-2 further reinforce the durability of response with mirikizumab. Among patients who achieved endoscopic response at week 52, the majority maintained benefit through 2 years. At week 104, 77.1% remained in clinical remission, while more than 80% sustained endoscopic response.

For clinicians, these findings provide an added layer of confidence, not only that mirikizumab can induce remission in a post–anti-TNF population, but that these responses are likely to persist with continued treatment.

Implications for Second-Line Treatment Sequencing in Crohn’s Disease

As the therapeutic landscape in Crohn’s disease continues to evolve, data like these help inform real-world decision-making. Mirikizumab’s demonstrated efficacy and durability in patients with prior anti-TNF exposure position it as a compelling second-line option, particularly in a setting where treatment attrition is common.

“These are important results for clinical practice, because often we're looking for data like this, how well does this match the patient that's going to walk in my door next and a clinical decision that I'm going to try to make?” Barnes said. “I think this is going to help people in their clinic with their clinical decision making.”

Editors’ note: Barnes reports relevant disclosures with AbbVie, Bristol-Meyers Squibb, Lilly, and Target RWE.

Gisbert JP, Ma C, Fantini MC, et al. MIRIKIZUMAB IS EFFICACIOUS IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE AFTER ONE PRIOR ANTI-TNF FAILURE. Presented at Digestive Disease Week (DDW) 2026; Chicago, IL; May 2–5, 2026.

Lilly. Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years. May 5, 2026. Accessed May 5, 2026. 

https://lilly.mediaroom.com/2026-05-05-Lillys-Omvoh-mirikizumab-mrkz-is-the-first-and-only-IL-23p19-to-demonstrate-durable-disease-clearance-in-ulcerative-colitis-through-four-years

Edward Barnes, MD, MPH, explains mirikizumab’s strong remission and durable response in Crohn’s disease patients after anti-TNF failure, supporting second-line use.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

VIVID Post Hoc Analysis Supports Mirikizumab After Anti-TNF Failure in Crohn’s Disease

Maria Abreu, MD, is Executive Director of the F. Widjaja Inflammatory Bowel Disease Institute at Cedars-Sinai.

Is Dual-Target Therapy the Future of Ulcerative Colitis? New Phase 2b JNJ-4804 Data

For patients with ulcerative colitis (UC) who have failed multiple lines of therapy, treatment options are limited and outcomes are often poor. A novel investigational approach simultaneously targeting 2 distinct inflammatory pathways with a single fixed-dose co-antibody may offer hope for changing that reality.

Phase 2b data from the DUET-UC trial presented at Digestive Disease Week (DDW) 2026 in Chicago, IL, by Maria Abreu, MD, Executive Director of the F. Widjaja Inflammatory Bowel Disease Institute at Cedars-Sinai, position JNJ-78934804 (JNJ-4804) as a potentially transformational therapy for one of the most difficult-to-treat populations in inflammatory bowel disease (IBD).

"Most of the advanced therapies in ulcerative colitis and Crohn's disease target one very specific thing." Abreu told 

. "I tell my patients an anti-TNF can only do one thing, it can only find TNF and block TNF. In the case of an anti IL-23, it could only do this one thing, so we view that these are 2 different aspects of the immune response, and so targeting these 2 orthogonal pathways makes intellectual sense.”

DUET-UC was a phase 2b, randomized, double-blind, dose-ranging study in which 572 patients with moderately to severely active UC were randomized to placebo, guselkumab, golimumab, or JNJ-4804 at low, mid, or high doses. The primary endpoint was clinical remission at Week 48.

Of note, the trial enrolled an unusually refractory population: all patients had inadequate response or intolerance to ≥ 1 systemic therapy class, 45% had failed ≥ 2, and some had cycled through 6 or more prior biologics across multiple mechanisms of action. At baseline, 72% had severe endoscopic disease.

"They enrolled a group of patients that no one wants in their study," Abreu said. "For the most part, studies want people who've never been on any therapy, or maybe they'll let one or two previous therapies. In this study, they said anyone who's been on more than one mechanism of action, not just one drug, but one mechanism of action, is allowed to enroll.”

In the overall population, high-dose JNJ-4804 was significantly superior to golimumab for clinical remission at Week 48 and performed similarly to guselkumab. Abreu noted that the most compelling findings, however, came from the highly refractory subgroup who had failed ≥ 2 systemic therapy classes.

In this population, high-dose JNJ-4804 demonstrated clinically meaningful improvements across all endpoints compared with both monotherapies and placebo, including a 28-point advantage over golimumab and a 12-point advantage over guselkumab in clinical remission rates. Benefits were similarly pronounced for corticosteroid-free remission, endoscopic improvement, and histologic remission with endoscopic improvement.

Abreu highlighted the molecular underpinning of these results, noting that earlier biopsy data from the VEGA study showed that combining anti-IL-23 and anti-TNF therapies produced far greater reductions in inflammatory gene expression and greater increases in epithelial repair pathways than either agent alone.

Safety events per 100 patient-years in the JNJ-4804 groups were comparable to or lower than those observed with the monotherapies. Serious infection rates were low across all arms, and no new safety signals emerged over the 48-week study period.

"There is no increase in adverse events," Abreu said. "And this was a 48-week study — it wasn't like a 12-week study. These people did fine, so I think that there's every reason to believe that in the larger studies, we're not going to unmask yet another side effect of the two together.”

Abreu expressed hope that the results would accelerate phase 3 development and encourage broader collaboration across companies to test additional combination permutations, a shift she described as long overdue for the field.

Editors’ note: Abreu reports relevant disclosures with AbbVie, Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences, Janssen Pharmaceuticals, Pfizer, and others.

Abreu M, Sands BE, Vermeire S, et al. EFFICACY AND SAFETY OF THE FIRST CO-ANTIBODY THERAPY, JNJ-78934804, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS REFRACTORY TO SYSTEMIC THERAPIES. Presented at Digestive Disease Week (DDW) 2026; Chicago, IL; May 2–5, 2026.

Johnson & Johnson. Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease. PR Newswire. Published May 05, 2026. Accessed May 05, 2026. 

https://www.prnewswire.com/news-releases/johnson--johnson-investigational-co-antibody-therapy-jnj-4804-shows-potential-to-raise-the-bar-for-clinical-efficacy-in-treating-refractory-inflammatory-bowel-disease-302761831.html

Feagan BG, Sands BE, Sandborn WJ, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. 

. 2023;8(4):307-320. doi:10.1016/S2468-1253(22)00427-7

Maria Abreu, MD, breaks down efficacy and safety data for dual-target co-antibody JNJ-4804, offering a potential new option for heavily pretreated UC patients.

DUET-UC Data Highlight Potential of Dual-Pathway Targeting in Refractory Ulcerative Colitis

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

April was a packed month for endocrinology, with several decisions by the 

 and multiple major trial results reported. Additionally, the 

American Association of Clinical Endocrinology (AACE) Annual Meeting 2026

 in Las Vegas, Nevada, capped off the month with a series of key clinician insights on everything from GLP-1s in 

With all of the news released over the last month, the editorial team at 

 have collected 8 of the most impactful headlines below. Catch up on anything you might have missed as we move into May:


FDA Proposes Exclusion of Multiple GLP-1 RAs from Bulks List, With Raechel Sood, NP


On April 30, the FDA announced a proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list. If approved, this decision could outright prevent medical facilities from compounding these medications, thereby cutting down on the risk of exposure to unapproved concentrations or distillations. Rachael Sood, NP, discusses the proposal and its implications for patients living with 

FDA Expands Teplizumab Approval to Children 1 Year & Older to Delay Type 1 Diabetes Onset


On April 22, the FDA announced an extension to its prior approval of teplizumab-mzwv, allowing for the treatment of children ≥1 year of age with stage 2 T1D. The decision is a result of positive data from the PETITE-T1D study, which demonstrated that the safety and tolerability of teplizumab in younger children is consistent with that of older populations.


FDA Approves Orforglipron (Foundayo) As First Daily GLP-1 Pill Without Food, Water Restrictions


On April 1, the FDA announced the groundbreaking approval of orforglipron, the first oral GLP-1 RA that can be taken at any time of day without restrictions on food and water intake. Based on results from the ATTAIN clinical trial program, orforglipron helps patients lose excess body weight and keep the weight off when taken alongside a reduced-calorie diet and increased physical activity.


Crinecerfont Reduces Glucocorticoid Doses in CAH, With Richard Auchus, MD, PhD


The CAHtalyst Adult study has indicated crinecerfont’s efficacy in reducing glucocorticoid doses among patients with classic congenital adrenal hyperplasia (CAH). These 2-year results from the ongoing trial were presented by Richard Auchus, MD, PhD, professor of pharmacology and internal medicine at the University of Michigan, at AACE 2026, and highlighted substantial retention during the entire 2-year extension of the trial.


Relacorilant Reduces HbA1c in Cushing’s Despite GLP-1 Treatment, With Julie Silverstein, MD


A secondary analysis of the GRACE trial has indicated relacorilant’s capacity for reducing cortisol in patients taking GLP-1 RAs for Cushing syndrome. Julie Silverstein, MD, medical director of the pituitary center and of the clinical trials units at WashU Medicine, discusses the difficult pathway between excess cortisol and a series of long-term health detriments, as well as relacorilant’s capacity to offset these connections.


Navigating Iodine Deficiencies and Excesses in Thyroid Health, With Shashank Joshi, MD


Delivered by Shashank Joshi at AACE 2026, this presentation highlights the risk of both too little and too much iodine in the body. Despite the former being well documented over the years, excess iodine can present with many the same symptoms and be just as dangerous. Joshi also covers the narrow window of opportunity between the 2 extremes, emphasizing the importance of managing iodine intake by monitoring the use of nutritional supplements and iodized salt – among other easy ways of overdosing.


Continuous Ketone Monitoring in Diabetes: Clinical Potential and Future Impact, With Rodolfo Galindo, MD


At AACE 2026, Rodolfo Galindo, MD, discussed the promising future of continuous ketone monitoring, which is currently in development in the US. Galindo described the devices as not solely built for measuring ketones, but also for uncovering patterns that point-in-time testing is incapable of capturing. Given that current measurements fail to reflect the body’s constant fluctuations, continuous monitoring can provide a more effective and productive method of predicting diabetic ketoacidosis.


Diabetes Dialogue: Expanding GLP-1 Usage Into Type 1 Diabetes With Viral Shah, MD

In this episode of Diabetes Dialogue, recorded on-site at AACE 2026, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, invite Viral Shah, MD, onto the show to discuss implementing GLP-1 RAs into T1D care. Shah points out the interplay between T1D and obesity, the latter of which is poorly controlled with standard insulin therapy. Given GLP-1 RAs’ efficacy in lowering excess adiposity, Shah posits that they could provide substantial and lasting benefits for patients.

Catch up on key clinician insights, major FDA decisions, groundbreaking trial results, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Type 2 Diabetes

Thyroid Disorders

8 Endocrinology Headlines You Missed in April 2026

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The phase 3 FUZION trial found guselkumab achieved increased fistula remission rates than placebo in perianal fistulizing Crohn's disease.

Guselkumab Shows Efficacy in Perianal Fistulizing Crohn's Disease in Phase 3 FUZION Trial

Updated results from the NordICC trial build upon previous 10 year findings and shed further light on once-only colonoscopy as a primary screening modality.

NordICC: Single Colonoscopy Cuts Colorectal Cancer Incidence but Not Mortality at 13 Years

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

In the ongoing JADE EXTEND trial, long-term treatment with abrocitinib led to sustained skin clearance and other improvements through 112 weeks.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Abrocitinib Therapy Effective in Patients with Atopic Dermatitis at 2 Years

JNJ-4804 phase 2b results showed higher week-48 remission rates in refractory ulcerative colitis and Crohn disease.

JNJ-4804 Phase 2b Data Show Higher Week-48 Remission in Refractory UC, Crohn Disease

Phase 4 dupilumab data show improvements in esophageal distensibility and disease-related structural changes and inflammation in the esophagus in EoE.

REMODEL: Dupilumab Improves Esophageal Distensibility in EoE at 24 Weeks

Long-term LUCENT-3 data show mirikizumab sustained disease clearance in ulcerative colitis through 4 years of treatment.

Stephanie Gold, MD, is an instructor of medicine at the Icahn School of Medicine at Mount Sinai and a gastroenterologist at the Mount Sinai Hospital.

Stephanie Gold, MD, explains prospective IBD-Metabolic Clinic data show GLP-1 RAs are safe and effective for weight management in IBD, with added benefits for bowel function and fatigue.

Strategic Alliance Partnership

Adding GLP-1 RA Therapy to Lifestyle Counseling Drives Weight Loss, Improves Outcomes in IBD

Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

FDA News

5 Nephrology Headlines You Missed in April 2026

Catch up on any data and perspectives presented at the American Association of Clinical Endocrinology Annual Meeting 2026.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

AACE 2026 Recap: 5 Key Presentations to Know

Syed-Mohammed Jafri, MD, is a Gastroenterologist and Transplant Hepatologist at Henry Ford Hospital.

New research underscores the risks and daily burden of TPN in SBS, with focus shifting toward reducing dependence and complications.

Latest News

Monocyte Aging Links to Non-Somatic Depression Symptoms, With Nicole Perez, PhD

Shorter Antibiotic Treatment After Adequate Biliary Drainage Non-Inferior in Acute Cholangitis

VIVID Post Hoc Analysis Supports Mirikizumab After Anti-TNF Failure in Crohn’s Disease

DUET-UC Data Highlight Potential of Dual-Pathway Targeting in Refractory Ulcerative Colitis

8 Endocrinology Headlines You Missed in April 2026